Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 371

1.

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J.

Hepatology. 2002 May;35(5):1164-71.

PMID:
11981766
2.

Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.

Pelletier G, Ducreux M, Gay F, Luboinski M, Hag├Ęge H, Dao T, Van Steenbergen W, Buffet C, Rougier P, Adler M, Pignon JP, Roche A.

J Hepatol. 1998 Jul;29(1):129-34.

PMID:
9696501
4.

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer Study Group of Japan.

Gastroenterology. 2006 Aug;131(2):461-9.

PMID:
16890600
5.

Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma.

Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M.

Hepatology. 1997 Nov;26(5):1156-61.

PMID:
9362356
6.

Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients.

Dumortier J, Chapuis F, Borson O, Davril B, Scoazec JY, Poncet G, Henry L, Boillot O, Mion F, Berger F, Partensky C, Paliard P, Valette PJ.

Dig Liver Dis. 2006 Feb;38(2):125-33. Epub 2006 Jan 4.

PMID:
16389002
7.

[Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session].

El Khaddari S, Gaudin JL, Abidi H, Picaud G, Rode A, Souquet JC.

Gastroenterol Clin Biol. 2002 Aug-Sep;26(8-9):728-34. French.

8.
9.

A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.

Mabed M, Esmaeel M, El-Khodary T, Awad M, Amer T.

Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.

PMID:
19453695
10.

Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience.

Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G.

Cancer. 1995 May 15;75(10):2427-34.

11.

Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.

Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, Hayashi S, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Yumoto Y, Mori T, Oda T.

Semin Oncol. 1997 Apr;24(2 Suppl 6):S6-38-S6-45.

PMID:
9151915
12.

Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.

Guiu B, Colin C, Cercueil JP, Loffroy R, Guiu S, Ferrant E, Jouve JL, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B.

Am J Clin Oncol. 2009 Jun;32(3):238-44. doi: 10.1097/COC.0b013e3181845529.

PMID:
19349854
13.

Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.

Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, Frericks B, Zender L, Malek NP, Greten TF, Kubicka S, Manns MP, Galanski M.

Hepatobiliary Pancreat Dis Int. 2007 Jun;6(3):259-66.

14.

Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K, Chayama K.

Cardiovasc Intervent Radiol. 2009 Jul;32(4):687-94. doi: 10.1007/s00270-009-9570-2. Epub 2009 May 15.

PMID:
19444503
15.

Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.

Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D.

J Gastroenterol Hepatol. 2009 Aug;24(8):1437-44. doi: 10.1111/j.1440-1746.2009.05863.x. Epub 2009 May 28.

PMID:
19486255
16.
17.

Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.

Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M; Liver Cancer Study Group of Japan.

AJR Am J Roentgenol. 2010 Mar;194(3):830-7. doi: 10.2214/AJR.09.3308.

PMID:
20173167
18.

Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.

Grieco A, Marcoccia S, Miele L, Marmiroli L, Caminiti G, Ragazzoni E, Cotroneo AR, Cefaro GA, Rapaccini GL, Gasbarrini G.

Hepatogastroenterology. 2003 Jan-Feb;50(49):207-12.

PMID:
12630024
19.

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST.

Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8. Epub 2007 Jul 12.

PMID:
17627902
20.

[Transarterial chemoembolization with high dose iodized oil for the treatment of large hepatocellular carcinoma].

Chen M, Li J, Zhang Y.

Zhonghua Zhong Liu Za Zhi. 2001 Mar;23(2):165-7. Chinese.

PMID:
11783027
Items per page

Supplemental Content

Write to the Help Desk